Skip to main content
. Author manuscript; available in PMC: 2010 Sep 1.
Published in final edited form as: Ann N Y Acad Sci. 2009 Sep;1174:88–98. doi: 10.1111/j.1749-6632.2009.05000.x

Figure 1. Three approaches to DC-based immune intervention in cancer.

Figure 1

1) Vaccines based on antigen with or without adjuvant that target DCs randomly. That might result in vaccine antigens being taken up by a “wrong” type of DCs in the periphery which might lead to “unwanted” type of immune response. Vaccine antigens could also flow to draining lymph nodes where they can be captured by resident DCs; 2) Vaccines based on ex-vivo generated tumor antigen-loaded DCs that are injected back into patients; and 3) specific in vivo DC targeting with anti-DC antibodies fused with antigens and with DC activators.